Ra Capital Management, L.P. bought $59.0M of SpyGlass Pharma (SGP)
Executed Feb 9, disclosed Feb 11, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 11), the stock returned -5.7% (delay-adjusted); from the execution session (Feb 9), +6.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 30 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 7 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.